Funding: This work was supported by the NIAID Team Contract NO1-AI-05394 to Advanced BioScience Laboratories and to the University of Massachusetts Medical School.
Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate
Article first published online: 10 AUG 2005
Journal of Medical Primatology
Volume 34, Issue 5-6, pages 226–236, October 2005
How to Cite
Pal, R., Wang, S., Kalyanaraman, V.S., Nair, B.C., Whitney, S., Keen, T., Hocker, L., Hudacik, L., Rose, N., Cristillo, A., Mboudjeka, I., Shen, S., Wu-Chou, T.-H., Montefiori, D., Mascola, J., Lu, S. and Markham, P. (2005), Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. Journal of Medical Primatology, 34: 226–236. doi: 10.1111/j.1600-0684.2005.00120.x
- Issue published online: 10 AUG 2005
- Article first published online: 10 AUG 2005
- Accepted April 14, 2005.
- neutralizing antibody;
- non-human primate;
Abstract: Immunization of macaques with multivalent DNA encoding gp120 genes from HIV-1 subtypes A, B, C and E and a gag gene followed by boosting with homologous gp120 proteins elicited strong anti-gp120 antibodies capable of neutralizing homologous and to a lesser degree heterologous HIV-1 isolates. Both Env- and Gag-specific cell mediated immune (CMI) responses were detected in the immunized animals. Following rectal challenge with an SHIV isolate encoding HIV-1Ba-Lenv, plasma viremia in the infected immunized animals was significantly lower than that observed in the naïve animals. Further, one of six immunized animals was completely protected whereas all six naïve animals were infected. These results demonstrate that a vaccine based on priming with a polyvalent DNA vaccine from multiple HIV-1 subtypes followed by boosting with homologous Env proteins elicits anti-HIV-1 immune responses capable of controlling rectal transmission of SHIVBa-L.